These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9407437)

  • 1. Aldosterone is a major factor in the progression of renal disease.
    Ibrahim HN; Rosenberg ME; Greene EL; Kren S; Hostetter TH
    Kidney Int Suppl; 1997 Dec; 63():S115-9. PubMed ID: 9407437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
    Ibrahim HN; Rosenberg ME; Hostetter TH
    Semin Nephrol; 1997 Sep; 17(5):431-40. PubMed ID: 9316211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin-aldosterone system and progression of renal disease.
    Rüster C; Wolf G
    J Am Soc Nephrol; 2006 Nov; 17(11):2985-91. PubMed ID: 17035613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 6. Sex and the renin angiotensin system: implications for gender differences in the progression of kidney disease.
    Sandberg K; Ji H
    Adv Ren Replace Ther; 2003 Jan; 10(1):15-23. PubMed ID: 12616459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical approach in regression of glomerulosclerosis.
    Stoian M; Radulian G; Chiţac D; Simion E; Stoica V
    Rom J Intern Med; 2007; 45(2):215-8. PubMed ID: 18333378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.
    Raij L
    Am J Hypertens; 2005 Apr; 18(4 Pt 2):95S-99S. PubMed ID: 15837551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone and progression of kidney disease.
    Cortinovis M; Perico N; Cattaneo D; Remuzzi G
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms.
    Wolf G
    Nephrologie; 1998; 19(7):451-6. PubMed ID: 9857383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone in progressive renal disease.
    Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
    Semin Nephrol; 2001 Nov; 21(6):573-9. PubMed ID: 11709805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered regulation of renin-angiotensin, endothelin and natriuretic peptide systems in rat kidney with chronic unilateral ureteral obstruction.
    Bae EH; Kim IJ; Park JW; Ma SK; Choi KC; Lee JU; Kim SW
    Urol Int; 2007; 79(2):170-6. PubMed ID: 17851289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endothelin system and its antagonism in chronic kidney disease.
    Dhaun N; Goddard J; Webb DJ
    J Am Soc Nephrol; 2006 Apr; 17(4):943-55. PubMed ID: 16540557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence and implications of aldosterone breakthrough.
    Bomback AS; Klemmer PJ
    Nat Clin Pract Nephrol; 2007 Sep; 3(9):486-92. PubMed ID: 17717561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA
    J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.
    Eräranta A; Kurra V; Tahvanainen AM; Vehmas TI; Kööbi P; Lakkisto P; Tikkanen I; Niemelä OJ; Mustonen JT; Pörsti IH
    J Hypertens; 2008 Aug; 26(8):1661-8. PubMed ID: 18622246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.